Camurus AB (publ) (FRA:7CA)

Market Cap	2.97B -3.2%
Revenue (ttm)	209.33M +21.3%
Net Income	67.97M +71.7%
EPS	1.13 +70.3%
Shares Out	n/a
PE Ratio	43.76
Forward PE	33.33
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	85
Open	48.32
Previous Close	48.62
Day's Range	48.32 - 48.32
52-Week Range	45.66 - 67.80
Beta	n/a
RSI	27.80
Earnings Date	Feb 12, 2026

About Camurus AB

Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029, which completed phase III clinical trials for the treatment of acromegaly, and phase III clinical trials to treat gastroenteropancreatic neuroendocri...

• Industry: Pharmaceutical Preparations
• Founded: 1991
• Employees: 285
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 7CA

Financial Performance

In 2025, Camurus AB's revenue was 2.27 billion, an increase of 21.30% compared to the previous year's 1.87 billion. Earnings were 735.57 million, an increase of 71.70%.

Financial numbers in SEK